Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $12.47 and last traded at $12.58, with a volume of 20999 shares. The stock had previously closed at $12.55.
Analyst Ratings Changes
A number of equities analysts have recently issued reports on RCUS shares. HC Wainwright reissued a "neutral" rating and set a $20.00 price objective on shares of Arcus Biosciences in a research report on Wednesday, November 6th. Wedbush reiterated an "outperform" rating and issued a $36.00 price target on shares of Arcus Biosciences in a report on Thursday, November 7th. Finally, Barclays increased their target price on Arcus Biosciences from $25.00 to $29.00 and gave the stock an "overweight" rating in a report on Friday, October 25th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Arcus Biosciences presently has an average rating of "Buy" and a consensus price target of $32.67.
View Our Latest Report on Arcus Biosciences
Arcus Biosciences Price Performance
The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.08. The firm has a market capitalization of $1.16 billion, a PE ratio of -4.04 and a beta of 0.84. The business has a 50-day moving average of $14.67 and a 200 day moving average of $15.72.
Insider Activity at Arcus Biosciences
In related news, CFO Robert C. Goeltz II sold 3,594 shares of the stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $15.00, for a total transaction of $53,910.00. Following the completion of the sale, the chief financial officer now directly owns 60,138 shares of the company's stock, valued at approximately $902,070. This trade represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 12.30% of the stock is owned by insiders.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of the business. Jane Street Group LLC boosted its holdings in shares of Arcus Biosciences by 59.8% in the 3rd quarter. Jane Street Group LLC now owns 217,041 shares of the company's stock worth $3,319,000 after buying an additional 81,193 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Arcus Biosciences by 11.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 566,979 shares of the company's stock worth $8,669,000 after acquiring an additional 59,536 shares during the period. GSA Capital Partners LLP raised its position in Arcus Biosciences by 17.8% in the third quarter. GSA Capital Partners LLP now owns 187,415 shares of the company's stock worth $2,866,000 after acquiring an additional 28,307 shares during the period. Parkman Healthcare Partners LLC boosted its stake in Arcus Biosciences by 146.9% in the third quarter. Parkman Healthcare Partners LLC now owns 1,025,754 shares of the company's stock valued at $15,684,000 after acquiring an additional 610,219 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in shares of Arcus Biosciences by 7.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 29,858 shares of the company's stock valued at $455,000 after acquiring an additional 2,123 shares during the period. Institutional investors own 92.89% of the company's stock.
About Arcus Biosciences
(
Get Free Report)
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.
Featured Stories
Before you consider Arcus Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcus Biosciences wasn't on the list.
While Arcus Biosciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
